GIIL Divita
Chief Executive Officer Aanastra Inc
Dr. Gilles DIVITA is Chief Scientist at AANASTRA Inc, California (USA), founder and CEO of DIVINCELL, BioPharmaceutical NanoMedicine companies that pioneering novel peptide-based RNA therapeutic drug delivery for the treatment of cancer and genetic diseases. Dr. DIVITA has over 25 years of experience in drug delivery systems, peptide-drugs and oligonucleotide therapeutics. He is the pioneer of the “non covalent cell penetrating peptide-based strategy” for therapeutic delivery. Dr. DIVITA worked as a Scientist at the Max Planck Institute for Medical Research in Heidelberg-Germany, Associate Professor at the SCRIPPS Research Institute, La Jolla, USA and as Director of of Chemical Biology and Nanotechnology for the Therapeutics Department at the CNRS in Montpellier-France.
Seminars
- Where do LNPs begin to show limitations for extrahepatic delivery and which emerging delivery vehicles offer the most realistic advantages?
- How do alternative delivery platforms compare in terms of manufacturability, scalability, safety, and regulatory readiness when moving towards the clinic?
- Which delivery challenges, from immunogenicity to targeting specificity, are best addressed by exploring non-LNP platforms, and where do LNPs remain the most practical solution?
- AI-driven design and optimization of a peptide-based targeted RNA delivery system
- PEP-NPTM: Highly selective, best-in-class, peptide nanoparticles for extrahepatic mRNA delivery
- In vivo mRNA based CAR-T cell engineering using novel targeted peptide-based nanoparticles
